Supernus Pharmaceuticals, Inc. (SUPN) Financials

Key financial figures for Supernus Pharmaceuticals, Inc. (Q1 2026).

Revenue

$208M

Net Income

-$2M

EPS

$-0.04

Total Assets

$1.5B

Operating Cash Flow

$67M

Full income statement, balance sheet, and cash flow for Supernus Pharmaceuticals, Inc. on SentiSense.